Evidence map›Paper›PMID 24405888›Full record

ArticleStem cell research & therapy2013

Human umbilical cord mesenchymal stromal cells exhibit immature nucleus pulposus cell phenotype in a laminin-rich pseudo-three-dimensional culture system.

Brian H Chon, Esther J Lee, Liufang Jing, Lori A Setton, Jun Chen

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. IGF Signaling in Intervertebral Disc Health and Disease.Frontiers in cell and developmental biology · 2021
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Cell therapy for the degenerating intervertebral disc.Translational research : the journal of laboratory and clinical medicine · 2017
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Inflammation in intervertebral disc degeneration and regeneration.Journal of the Royal Society, Interface · 2015
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Brian H Chon
Esther J Lee
Liufang Jing
Lori A Setton
Jun Chen

Funding

MECHANICAL STIMULATION OF IVD CELLSR01AR047442 · NIAMS · WASHINGTON UNIVERSITY · PI SETTON, LORI A. · 2001 to 2015
$4.6M
Genetically Designed/Tissue-Engineered Meniscal RepairR01EB002263 · NIBIB · DUKE UNIVERSITY · PI SETTON, LORI A. · 2003 to 2010
$3.2M
Developing Immature Nucleus Pulposus Cells for Regenerative TherapyR01AR057410 · NIAMS · DUKE UNIVERSITY · PI CHEN, JUN · 2009 to 2013
$1.2M
NIAMS NIH HHS R01 AR047442NIAMS NIH HHS R01AR047442NIAMS NIH HHS R01 AR057410NIAMS NIH HHS R01AR057410NIBIB NIH HHS R01 EB002263NIBIB NIH HHS R01EB002263
6 · The paper itself

Abstract

introductionCell supplementation to the herniated or degenerated intervertebral disc (IVD) is a potential strategy to promote tissue regeneration and slow disc pathology. Human umbilical cord mesenchymal stromal cells (HUCMSCs) - originating from the Wharton's jelly - remain an attractive candidate for such endeavors with their ability to differentiate into multiple lineages. Previously, mesenchymal stem cells (MSCs) have been studied as a potential source for disc tissue regeneration. However, no studies have demonstrated that MSCs can regenerate matrix with unique characteristics matching that of immature nucleus pulposus (NP) tissues of the IVD. In our prior work, immature NP cells were found to express specific laminin isoforms and laminin-binding receptors that may serve as phenotypic markers for evaluating MSC differentiation to NP-like cells. The goal of this study is to evaluate these markers and matrix synthesis for HUCMSCs cultured in a laminin-rich pseudo-three-dimensional culture system.

methodsHUCMSCs were seeded on top of Transwell inserts pre-coated with Matrigel™, which contained mainly laminin-111. Cells were cultured under hypoxia environment with three differentiation conditions: NP differentiation media (containing 2.5% Matrigel™ solution to provide for a pseudo-three-dimensional laminin culture system) with no serum, or the same media supplemented with either insulin-like growth factor-1 (IGF-1) or transforming growth factor-β1 (TGF-β1). Cell clustering behavior, matrix production and the expression of NP-specific laminin and laminin-receptors were evaluated at days 1, 7, 13 and 21 of culture.

resultsData show that a pseudo-three-dimensional culture condition (laminin-1 rich) promoted HUCMSC differentiation under no serum conditions. Starting at day 1, HUCMSCs demonstrated a cell clustering morphology similar to that of immature NP cells in situ and that observed for primary immature NP cells within the similar laminin-rich culture system (prior study). Differentiated HUCMSCs under all conditions were found to contain glycosaminoglycan, expressed extracellular matrix proteins of collagen II and laminin α5, and laminin receptors (integrin α3 and β4 subunits). However, neither growth factor treatment generated distinct differences in NP-like phenotype for HUCMSC as compared with no-serum conditions.

conclusionsHUCMSCs have the potential to differentiate into cells sharing features with immature NP cells in a laminin-rich culture environment and may be useful for IVD cellular therapy.

Indexed as

Cell Culture TechniquesCell DifferentiationCell HypoxiaCells, CulturedCluster AnalysisCollagen Type IIExtracellular MatrixGene ExpressionGlycosaminoglycansHumansInsulin-Like Growth Factor IIntegrin alpha3Integrin beta4Intervertebral DiscLamininMesenchymal Stem CellsCollagen Type IIGlycosaminoglycansInsulin-Like Growth Factor IIntegrin alpha3Integrin beta4Lamininlaminin alpha5Transforming Growth Factor beta1

Identifiers

PMID24405888
PMCPMC3854685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.